StreetInsider.com News Articles

Form 8-K Polaryx Therapeutics, For: Jul 16

Fri, 17 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260717/26782106.html

H.C. Wainwright Starts Polaryx Therapeutics (PLYX) at Buy

Thu, 09 Jul 2026 06:45:21 -0400

H.C. Wainwright analyst Raghuram Selvaraju initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Buy rating and a price target of $7.00.

The analyst comments "PLX-200 targets fatal pediatric CNS-LSDs with a repurposed oral drug with impressive data, yet a ~$100M EV gives little credit. We are initiating coverage of Polaryx Therapeutics with a Buy rating and $7 PT, driven by what we view as an underappreciated orphan-disease setup: PLX-200 uses a long-approved active ingredient, targets shared downstream lysosomal dysfunction across severe pediatric CNS-LSDs, and enters SOTERIA with preclinical evidence of target engagement, cellular waste reduction, motor benefit, and survival extension

H.C. Wainwright Starts Polaryx Therapeutics (PLYX) at Buy

Thu, 09 Jul 2026 06:45:21 -0400

H.C. Wainwright analyst Raghuram Selvaraju initiates coverage on Polaryx Therapeutics (NASDAQ: PLYX) with a Buy rating and a price target of $7.00.

Form 4 Polaryx Therapeutics, For: May 27 Filed by: Yang Alex Keun Mo

Thu, 28 May 2026 20:01:00 -0400

si-local-file:///var/storage/secattach/20260528/26569357.html

Form 8-K Polaryx Therapeutics, For: May 27

Thu, 28 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260528/26567994.html

Polaryx Therapeutics raises $10 million to fund phase 2 trial

Thu, 28 May 2026 08:30:35 -0400

Polaryx Therapeutics Inc. (NASDAQ: PLYX) closed a $10 million private investment in public equity financing on May 28, 2026, the clinical-stage biotechnology company announced.

The financing consisted of 2,502,696 shares of common stock sold at an average price of approximately $4.00 per share. Polaryx develops therapies for rare pediatric lysosomal storage disorders.

The company plans to use the proceeds along with existing cash to fund the initiation of its Phase 2 SOTERIA trial, which will evaluate PLX-200 across multiple lysosomal storage disorder indications. The funds will also support continued research and development of product candidates and general corporate purposes.

"This financing provides us

Polaryx Therapeutics raises $10 million to fund phase 2 trial

Thu, 28 May 2026 08:30:35 -0400

Polaryx Therapeutics Inc. (NASDAQ: PLYX) closed a $10 million private investment in public equity financing on May 28, 2026, the clinical-stage biotechnology company announced.

The financing consisted of 2,502,696 shares of common stock sold at an average price of approximately $4.00 per share. Polaryx develops therapies for rare pediatric lysosomal storage disorders.

"This financing provides us

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

Thu, 28 May 2026 08:30:00 -0400

PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that it has closed a private investment in public equity (“PIPE”) financing resulting in proceeds of $10 million. The PIPE financing closed on May 28, 2026.

The PIPE financing consisted of an aggregate of 2,502,696 shares of common stock at an average purchase price of approximately $4.00 per share.

Polaryx intends to use the net proceeds from the PIPE

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

Thu, 28 May 2026 08:30:00 -0400

The PIPE financing consisted of an aggregate of 2,502,696 shares of common stock at an average purchase price of approximately $4.00 per share.

Polaryx intends to use the net proceeds from the PIPE

Form 10-Q Polaryx Therapeutics, For: Mar 31

Fri, 15 May 2026 06:13:00 -0400

si-local-file:///var/storage/secattach/20260515/26498506.html

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards

Thu, 14 May 2026 09:15:00 -0400

Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner

PARAMUS, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), announces that it has been named a double winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as both the Best Pediatric Lysosomal Storage Disease Therapeutics 2026 - USA and the Rare Neurodegenerative Disease Drug Development Excellence Award 2026 - USA awards recipient.

“While current treatments have pushed care forward for

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards

Thu, 14 May 2026 09:15:00 -0400

Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner

“While current treatments have pushed care forward for

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards

Thu, 14 May 2026 09:15:00 -0400

“While current treatments have pushed care forward for lysosomal storage disorders, children and their families still face a significant daily treatment burden,” said Alex Yang,

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards

Thu, 14 May 2026 09:15:00 -0400

“While current treatments have pushed care forward for lysosomal storage disorders, children and their families still face a significant daily treatment burden,” said Alex Yang,

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

Thu, 23 Apr 2026 08:30:00 -0400

PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced its participation in the National Tay-Sachs & Allied Diseases Association (NTSAD) Annual Family Conference, taking place April 30 through May 3, 2026, at the Hyatt Regency in Reston, Virginia.

“The NTSAD Annual Family Conference is an important opportunity to connect directly with the families and advocates at the heart of the rare disease community,” said Alex Yang, J.D., LL.M., Chief Executive Officer of Polaryx Therapeutics. “These interactions

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

Thu, 23 Apr 2026 08:30:00 -0400

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

Thu, 23 Apr 2026 08:30:00 -0400

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

Thu, 23 Apr 2026 08:30:00 -0400

Polaryx receives FDA fast track status for four rare disease treatments

Tue, 21 Apr 2026 08:30:58 -0400

Polaryx Therapeutics Inc. (NASDAQ: PLYX) announced that the U.S. Food and Drug Administration granted Fast Track Designation to PLX-200 for treating three additional rare pediatric diseases: Juvenile Neuronal Ceroid Lipofuscinosis, Krabbe disease, and Sandhoff disease.

The designations follow a March 2026 Fast Track grant for PLX-200 in treating Late-Infantile Neuronal Ceroid Lipofuscinosis. PLX-200 now holds Fast Track status for all four indications planned for evaluation in the company's SOTERIA Phase 2 basket trial.

The FDA's Fast Track program expedites review of therapies for serious conditions with unmet medical need. Companies with this designation receive more frequent FDA interactions and potential rolling review

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Tue, 21 Apr 2026 08:30:00 -0400

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II).

Following the March 2026 grant of FTD to PLX-200 in treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease), PLX-200 now holds FTD for all four prospective indications to be studied in

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Tue, 21 Apr 2026 08:30:00 -0400

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Wed, 15 Apr 2026 09:15:00 -0400

PARAMUS, NJ, April 15, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), announces that it has been named a winner of the 2026 Pinnacle Awards for Healthcare, being selected as a Diamond honoree for Excellence in Pediatric Care.

Polaryx was recognized for its innovative and scalable approach to treating lysosomal storage disorders (LSDs), a group of rare genetic diseases that cause progressive neurological decline and early mortality. Rather than developing therapies for individual conditions in isolation, the

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Wed, 15 Apr 2026 09:15:00 -0400

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Wed, 15 Apr 2026 09:15:00 -0400

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Wed, 15 Apr 2026 09:15:00 -0400